Aspirin for the Precision Prevention of Colorectal Cancer
Andrew T. Chan, M.D., M.P.H. is a Professor of Medicine at Harvard Medical School (HMS), Chief of the Clinical and Translational Epidemiology Unit, and the Program Director for gastroenterology training at Massachusetts General Hospital (MGH). As a clinical gastroenterologist, Dr. Chan specializes in familial gastrointestinal cancer syndromes and cancer prevention. Dr. Chan is a leading investigator in the epidemiology of colorectal cancer and other digestive diseases, with a focus on chemoprevention with aspirin and the interaction of diet with the gut microbiome. An elected fellow of the American Society of Clinical Investigation, he currently supported by NCI to conduct a randomized trial of aspirin in relation to colorectal cancer biomarkers. He has published over 385 papers in the field of colorectal cancer and other chronic digestive diseases in leading journals, including the New England Journal of Medicine, Journal of the American Medical Association, Lancet, Science Translational Medicine, Gastroenterology and Gut. Dr Chan is a section editor for Gastroenterology, serves on the editorial board of Cancer Prevention Research and Cancer Epidemiology Biomarkers and Prevention, and is vice-chair of the Gastrointestinal Oncology Section of the AGA.